These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease. Sofic E; Riederer P; Wesemann W; Kienzl E; Eichinger K; Gsell W; Jellinger K J Neural Transm Park Dis Dement Sect; 1991; 3(4):265-71. PubMed ID: 1772579 [TBL] [Abstract][Full Text] [Related]
43. Decreased dopamine in the retinas of patients with Parkinson's disease. Harnois C; Di Paolo T Invest Ophthalmol Vis Sci; 1990 Nov; 31(11):2473-5. PubMed ID: 2243012 [TBL] [Abstract][Full Text] [Related]
44. The locus coeruleus: Another vulnerability target in Parkinson's disease. Oertel WH; Henrich MT; Janzen A; Geibl FF Mov Disord; 2019 Oct; 34(10):1423-1429. PubMed ID: 31291485 [No Abstract] [Full Text] [Related]
45. Somatic transposition in the brain has the potential to influence the biosynthesis of metabolites involved in Parkinson's disease and schizophrenia. Abrusán G Biol Direct; 2012 Nov; 7():41. PubMed ID: 23176288 [TBL] [Abstract][Full Text] [Related]
46. Endogenous dopamine release in Parkinson's disease. Rinne JO Lancet Neurol; 2003 Aug; 2(8):460-1. PubMed ID: 12878432 [No Abstract] [Full Text] [Related]
47. Parkinson's Disease: The Life Cycle of the Dopamine Neuron. September 18-20, 2002. Princeton, New Jersey, USA. Proceedings. Ann N Y Acad Sci; 2003 Jun; 991():1-360. PubMed ID: 12846968 [No Abstract] [Full Text] [Related]
48. Parkinson's disease, depression, and electroconvulsive therapy: a clinical and neurobiologic synthesis. Yudofsky SC Compr Psychiatry; 1979; 20(6):579-81. PubMed ID: 41677 [No Abstract] [Full Text] [Related]